On Sept. 1, the U.S. Food and Drug Administration (FDA) approved Mylotarg (gemtuzumab ozogamicin) for the treatment of adults with newly diagnosed acute myeloid leukemia whose tumors express the CD33 antigen (CD33-positive AML) and for he treatment of patients aged 2 years and older with CD33-positive AML who have experienced a relapse or are refractory to initial treatment.

Via FDA.gov